Strides Pharma Science Limited — Updates, 24-10-2024: Press Release

Strides Pharma Science reported strong Q2FY25 results with revenues of ₹12,011m, up 17% YoY, and a historic US revenue of $75m, growing 26% YoY. EBITDA rose 31% YoY to ₹2,358m, with an EBITDA margin of 19.6%. Adjusted PAT stood at ₹1,103m. The company launched a Sustainability Report and secured $95m in fundraising. Looking ahead, Strides aims for ongoing revenue growth, increased profitability, and reduced net debt while enhancing its operational efficiency.